PURPOSE: We aimed to investigate the correlations between the expression of VEGF, PDGF-B, and their receptors (VEGFR2 and PDGFR-β) with pathologic stage or cell type in non-metastatic renal cell carcinoma. MATERIALS AND METHODS: VEGF, VEGFR2, PDGF-B, and PDGFR-β protein expression were evaluated immunohistochemically in prospectively collected 1,423 tumour samples obtained during radical or partial nephrectomy at a tertiary referral center. Intensity of expression was quantified on a scale of 0 to 3, and was compared among renal cell carcinoma cell types. RESULTS: The study cohort consisted of 1,091 patients, of mean age 54 years, including 968 (88.7%) with clear cell, 82 (7.5%) with papillary, 31 (2.8%) with chromophobe, 4 (0.4%) with unclassified, and 6 (0.5%) with other types of renal cell carcinoma. VEGF expression increased with higher T and N stage and Fuhrman nuclear grade. PDGFR-β expression was highest in clear cell renal cell carcinoma, whereas VEGF and PDGF-B expression were highest in papillary renal cell carcinoma. After adjusting for T stage and Fuhrman nuclear grade using multivariate logistic regression analysis, VEGF (OR = 3.57, P < 0.001), VEGFR2 (OR = 1.82, P = 0.017), and PDGF-B (OR = 2.46, P = 0.019) expression were significantly greater in papillary than in clear cell type. CONCLUSIONS: Our results indicate that the cytoplasmic expression of VEGF, VEGFR2, PDGF-B, and PDGFR-β in RCC tumour cells is different in various pathologic stage and cell type. Notably, VEGF and PDGF-B expression are higher in papillary than in clear cell renal cell carcinoma. Further studies using quantitative measurement of proangiogenic factors in tumour cell are needed.
PURPOSE: We aimed to investigate the correlations between the expression of VEGF, PDGF-B, and their receptors (VEGFR2 and PDGFR-β) with pathologic stage or cell type in non-metastatic renal cell carcinoma. MATERIALS AND METHODS:VEGF, VEGFR2, PDGF-B, and PDGFR-β protein expression were evaluated immunohistochemically in prospectively collected 1,423 tumour samples obtained during radical or partial nephrectomy at a tertiary referral center. Intensity of expression was quantified on a scale of 0 to 3, and was compared among renal cell carcinoma cell types. RESULTS: The study cohort consisted of 1,091 patients, of mean age 54 years, including 968 (88.7%) with clear cell, 82 (7.5%) with papillary, 31 (2.8%) with chromophobe, 4 (0.4%) with unclassified, and 6 (0.5%) with other types of renal cell carcinoma. VEGF expression increased with higher T and N stage and Fuhrman nuclear grade. PDGFR-β expression was highest in clear cell renal cell carcinoma, whereas VEGF and PDGF-B expression were highest in papillary renal cell carcinoma. After adjusting for T stage and Fuhrman nuclear grade using multivariate logistic regression analysis, VEGF (OR = 3.57, P < 0.001), VEGFR2 (OR = 1.82, P = 0.017), and PDGF-B (OR = 2.46, P = 0.019) expression were significantly greater in papillary than in clear cell type. CONCLUSIONS: Our results indicate that the cytoplasmic expression of VEGF, VEGFR2, PDGF-B, and PDGFR-β in RCC tumour cells is different in various pathologic stage and cell type. Notably, VEGF and PDGF-B expression are higher in papillary than in clear cell renal cell carcinoma. Further studies using quantitative measurement of proangiogenic factors in tumour cell are needed.
Authors: Tatiana V Petrova; Petri Bono; Wolfgang Holnthoner; Jessica Chesnes; Bronislaw Pytowski; Harri Sihto; Pirjo Laakkonen; Päivi Heikkilä; Heikki Joensuu; Kari Alitalo Journal: Cancer Cell Date: 2008-06 Impact factor: 31.743
Authors: Tania Romina Stoyanoff; Juan Pablo Rodríguez; Juan Santiago Todaro; Joaquín Diego Espada; Juan Pablo Melana Colavita; Nora Cristina Brandan; Adriana Mónica Torres; María Victoria Aguirre Journal: Tumour Biol Date: 2016-07-28
Authors: Sumanta K Pal; Catherine Tangen; Ian M Thompson; Naomi Balzer-Haas; Daniel J George; Daniel Y C Heng; Brian Shuch; Mark Stein; Maria Tretiakova; Peter Humphrey; Adebowale Adeniran; Vivek Narayan; Georg A Bjarnason; Ulka Vaishampayan; Ajjai Alva; Tian Zhang; Scott Cole; Melissa Plets; John Wright; Primo N Lara Journal: Lancet Date: 2021-02-13 Impact factor: 79.321
Authors: Magnus Frödin; Artur Mezheyeuski; Sara Corvigno; Ulrika Harmenberg; Per Sandström; Lars Egevad; Martin Johansson; Arne Östman Journal: Br J Cancer Date: 2016-12-08 Impact factor: 7.640
Authors: Jenny J Ko; Jasleen K Grewal; Tony Ng; Jean-Michel Lavoie; My Linh Thibodeau; Yaoqing Shen; Andrew J Mungall; Greg Taylor; Kasmintan A Schrader; Steven J M Jones; Christian Kollmannsberger; Janessa Laskin; Marco A Marra Journal: Cold Spring Harb Mol Case Stud Date: 2018-12-17